Franklin Genomic Advancements ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Franklin Genomic Advancements ETF HELX
Morningstar’s Analysis HELX
Will HELX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Natera Inc | 10.27 | 3M | Healthcare |
Guardant Health Inc | 9.68 | 3M | Healthcare |
Twist Bioscience Corp | 5.21 | 2M | Healthcare |
Krystal Biotech Inc | 5.07 | 2M | Healthcare |
Adaptive Biotechnologies Corp | 4.66 | 2M | Healthcare |
Ligand Pharmaceuticals Inc | 4.41 | 1M | Healthcare |
BridgeBio Pharma Inc | 2.88 | 941,156 | Healthcare |
United Therapeutics Corp | 2.67 | 875,354 | Healthcare |
Travere Therapeutics Inc Ordinary Shares | 2.63 | 861,448 | Healthcare |
Medpace Holdings Inc | 2.59 | 846,283 | Healthcare |